Omeros (NASDAQ:OMER) Stock Price Crosses Above Two Hundred Day Moving Average - Here's What Happened

Key Points

• Omeros stock crossed above its 200‑day moving average, trading as high as $15.25 and last at $14.91 on volume of 1,087,871 shares versus a 200‑day MA of $11.05.
• The company reported a surprise quarterly EPS of $3.14, beating the -$0.55 estimate, although analysts still project -1.54 EPS for the current fiscal year.
• Analyst and institutional views are mixed: MarketBeat shows a "Moderate Buy" consensus with a $40.33 target while ratings range from Strong Buy to Sell, and institutions now own about 48.79% of the stock after recent stake increases.

Shares of Omeros Corporation (NASDAQ:OMER - Get Free Report) crossed above its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $11.05 and traded as high as $15.25. Omeros shares last traded at $14.91, with a volume of 1,087,871 shares traded.

Analyst Ratings Changes

Several equities analysts recently commented on OMER shares. Zacks Research raised shares of Omeros from a "hold" rating to a "strong-buy" rating in a research report on Thursday, April 2nd. Wall Street Zen downgraded shares of Omeros from a "buy" rating to a "hold" rating in a research note on Sunday, April 26th. HC Wainwright boosted their price objective on shares of Omeros from $20.00 to $40.00 and gave the stock a "buy" rating in a research note on Thursday, January 8th. D. Boral Capital reiterated a "buy" rating and set a $36.00 price objective on shares of Omeros in a research note on Tuesday, April 21st. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of Omeros in a research note on Tuesday, April 21st. Two analysts have rated the stock with a Strong Buy rating, two have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $40.33.

Omeros Stock Down 1.0%

The firm's 50 day simple moving average is $11.82 and its 200-day simple moving average is $11.05. The company has a market capitalization of $1.07 billion, a PE ratio of -29.82 and a beta of 2.66.

Omeros (NASDAQ:OMER - Get Free Report) last released its quarterly earnings data on Tuesday, March 31st. The biopharmaceutical company reported $3.14 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.55) by $3.69. As a group, sell-side analysts anticipate that Omeros Corporation will post -1.54 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in OMER. UBS Group AG boosted its stake in shares of Omeros by 213.5% in the fourth quarter. UBS Group AG now owns 2,222,982 shares of the biopharmaceutical company's stock valued at $38,180,000 after purchasing an additional 1,513,893 shares during the period. Vanguard Group Inc. boosted its stake in shares of Omeros by 19.9% in the fourth quarter. Vanguard Group Inc. now owns 4,013,315 shares of the biopharmaceutical company's stock valued at $68,929,000 after purchasing an additional 666,357 shares during the period. JPMorgan Chase & Co. boosted its stake in shares of Omeros by 1,201.1% in the third quarter. JPMorgan Chase & Co. now owns 416,153 shares of the biopharmaceutical company's stock valued at $1,706,000 after purchasing an additional 384,168 shares during the period. State Street Corp boosted its stake in shares of Omeros by 26.9% in the fourth quarter. State Street Corp now owns 1,573,526 shares of the biopharmaceutical company's stock valued at $27,025,000 after purchasing an additional 333,798 shares during the period. Finally, Two Sigma Investments LP boosted its stake in shares of Omeros by 39.3% in the third quarter. Two Sigma Investments LP now owns 933,314 shares of the biopharmaceutical company's stock valued at $3,827,000 after purchasing an additional 263,095 shares during the period. 48.79% of the stock is currently owned by hedge funds and other institutional investors.

About Omeros

Omeros Corporation is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small-molecule and protein therapeutics. The company's research programs target inflammation, complement-mediated diseases and disorders of the central nervous system. Omeros's portfolio encompasses both internally discovered molecules and biologics, reflecting its commitment to advancing treatments for conditions with high unmet medical need.

Omeros's first FDA-approved product, Omidria® (phenylephrine and ketorolac intraocular solution), is indicated to maintain pupil size by preventing intraoperative miosis and reducing postoperative pain in patients undergoing cataract surgery.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.